RxDoctor Payments DataLook up a doctor →

Ma Francesca Chamian, MD

Family Medicine · Las Vegas, NVNPI 1902088503

Payments from drug & device makers

$16,766in general payments, 2019–2025

Across 912 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Esperion Therapeutics, Inc.$861
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$16,694100%
  • Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,766 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$205,595
Medicare patients
377
Services billed
1,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate65$80,534
OzempicSemaglutide42$54,624
FarxigaDapagliflozin Propanediol33$38,717
JardianceEmpagliflozin24$30,011
MounjaroTirzepatide20$22,952
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$13,203
SynthroidLevothyroxine Sodium44$3,937
Levothyroxine Sodium278$2,537
Atorvastatin Calcium410$2,385
Ezetimibe87$2,315
Valsartan68$2,112
Losartan Potassium255$1,694
Amlodipine Besylate266$1,664
Pravastatin Sodium147$1,587
Omeprazole93$1,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$56$80,53465 claims
Novo NordiskOzempic$2,132$54,62442 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,922$51,92045 claims
Boehringer IngelheimJardiance$592$30,01124 claims
Lilly USA, LLCMounjaro$1,076$22,95220 claims
AbbVieSynthroid$822$3,93744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →